In order to examine whether sensitivity to sorafenib may correlate with VEGFR2 levels in thyroid cancer cells, Shaik et al. [31] treated cultured human cancer cells expressing different levels of VEGFR2 with different concentrations of sorafenib. The gene discussed is KDR; the disease is thyroid cancer.